ANI Pharmaceuticals’ (ANIP) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a research note released on Monday morning,Benzinga reports. The firm currently has a $94.00 price objective on the specialty pharmaceutical company’s stock.

A number of other brokerages have also recently weighed in on ANIP. Truist Financial lifted their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. StockNews.com downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Raymond James increased their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Finally, Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 price objective for the company. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, ANI Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $77.33.

ANI Pharmaceuticals Trading Down 1.5 %

NASDAQ ANIP opened at $58.91 on Monday. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The stock has a market capitalization of $1.24 billion, a P/E ratio of -107.11 and a beta of 0.71. The firm’s 50-day moving average is $58.48 and its two-hundred day moving average is $61.41. ANI Pharmaceuticals has a 12 month low of $48.20 and a 12 month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. The business had revenue of $148.30 million for the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business’s revenue was up 12.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.05 EPS. On average, sell-side analysts anticipate that ANI Pharmaceuticals will post 3.5 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Texas Permanent School Fund Corp raised its position in shares of ANI Pharmaceuticals by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 13,194 shares of the specialty pharmaceutical company’s stock worth $912,000 after acquiring an additional 172 shares in the last quarter. Louisiana State Employees Retirement System raised its holdings in ANI Pharmaceuticals by 2.7% during the second quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock worth $490,000 after purchasing an additional 200 shares in the last quarter. Arizona State Retirement System raised its holdings in ANI Pharmaceuticals by 4.7% during the second quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock worth $299,000 after purchasing an additional 211 shares in the last quarter. Simplicity Wealth LLC lifted its position in shares of ANI Pharmaceuticals by 3.5% during the 2nd quarter. Simplicity Wealth LLC now owns 6,733 shares of the specialty pharmaceutical company’s stock worth $429,000 after buying an additional 227 shares during the last quarter. Finally, California State Teachers Retirement System boosted its holdings in shares of ANI Pharmaceuticals by 1.5% in the 1st quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock valued at $1,118,000 after buying an additional 233 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.